News

US FDA approves PTC Therapeutics' metabolic disorder drug
The U.S. Food and Drug Administration has approved PTC Therapeutics' oral drug to treat a rare inherited metabolic disorder ...
Leerink Partners Maintains a Buy on BioMarin Pharmaceutical (BMRN), Retains a $105 PT
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is one of the most profitable biotech stocks to invest in now. On July 23, analyst Joseph Schwartz of Leerink Partners reiterated a Buy rating on BioMarin ...